Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KS-01
- Development stage
- Preclinical
- Lead developer
- CarboHyde
- Modality
- Small Molecules
01
Overview
KS-01 is a cyclic amylose oligomer composed of glucose units, currently in preclinical development as a novel anticancer agent. Its primary mechanism of action involves depleting intracellular cholesterol, which is crucial for cancer cell membrane integrity and proliferation. This cholesterol depletion leads to significant growth inhibition and apoptosis in cancer cells, including both estrogen-positive (ER+) and estrogen-negative (ER-) breast cancer cell lines. The compound has been shown to be toxicologically benign in humans in other contexts, suggesting a favorable safety profile for further development. It is being investigated by the University of the Witwatersrand and CarboHyde.
Beyond the preview
Go deeper on KS-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KS-01.